Catálogo de publicaciones - libros
Cachexia and Wasting: A Modern Approach
Giovanni Mantovani ; Stefan D. Anker ; Akio Inui ; John E. Morley ; Filippo Rossi Fanelli ; Daniele Scevola ; Michael W. Schuster ; Shing-Shing Yeh (eds.)
Resumen/Descripción – provisto por la editorial
No disponible.
Palabras clave – provistas por la editorial
Oncology; Internal Medicine; Geriatrics/Gerontology; Infectious Diseases; Metabolic Diseases
Disponibilidad
| Institución detectada | Año de publicación | Navegá | Descargá | Solicitá |
|---|---|---|---|---|
| No detectada | 2006 | SpringerLink |
Información
Tipo de recurso:
libros
ISBN impreso
978-88-470-0471-9
ISBN electrónico
978-88-470-0552-5
Editor responsable
Springer Nature
País de edición
Reino Unido
Fecha de publicación
2006
Información sobre derechos de publicación
© Springer-Verlag Italia 2006
Cobertura temática
Tabla de contenidos
Cachexia: Therapeutic Immunomodulation Beyond Cytokine Antagonism
Stephan von Haehling; Stefan D. Anker
Cachexia is frequently observed in a number of different chronic illnesses. Although a final common pathway has not yet been established, a number of features have been recognised irrespective of underlying aetiology. These aspects of the disease include activation of the immune system, muscle wasting through the ubiquitin-proteasome pathway and endothelial dysfunction. Targeting these aspects of cachexia involves downstream signalling of proinflammatory cytokines, proteasome inhibition and possibly the use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins). Apart from their cholesterollowering features, the latter class of drugs has recently been shown to improve endothelial dysfunction, to induce endothelial progenitor cells, and to have anti-inflammatory properties. These features have recently b een termed p leiotropic effects of statins. It is therefore tempting to speculate that cachectic patients will benefit from treatment with statins, and possibly also from immunosuppression per se.
Palabras clave: Chronic Heart Failure; Statin Therapy; Proteasome Inhibitor; Endothelial Progenitor Cell; Cancer Cachexia.
Section 12 - A Global Perspective for the Treatment of Cachexia | Pp. 741-753